MCID: GRD007
MIFTS: 61

Grade Iii Astrocytoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Grade Iii Astrocytoma

MalaCards integrated aliases for Grade Iii Astrocytoma:

Name: Grade Iii Astrocytoma 12 53 15
Anaplastic Astrocytoma 12 53 59 55 15 73
Grade Iii Astrocytic Tumor 12
Astrocytoma, Anaplastic 6

Characteristics:

Orphanet epidemiological data:

59
anaplastic astrocytoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3078
MeSH 44 D001254
SNOMED-CT 68 55353007
Orphanet 59 ORPHA251589
UMLS via Orphanet 74 C0334579
ICD10 via Orphanet 34 C71.9
UMLS 73 C0334579

Summaries for Grade Iii Astrocytoma

NIH Rare Diseases : 53 Anaplastic astrocytoma is a rare, cancerous (malignant) type of brain tumor that arises from star-shaped brain cells called astrocytes. These cells surround and protect nerve cells in the brain and spinal cord. An anaplastic astrocytoma usually develops slowly over time, but may develop rapidly. Signs and symptoms vary depending on the location and size of the tumor and may include headaches, drowsiness, vomiting, and changes in personality or mental status. Some affected people have seizures, vision problems, weakness of the limbs, and/or coordination problems. Anaplastic astroctyomas usually occur sporadically but can be associated with a few rare, genetic disorders. Treatment may include surgery, radiation, and/or chemotherapy.

MalaCards based summary : Grade Iii Astrocytoma, also known as anaplastic astrocytoma, is related to glioma susceptibility 1 and oligoastrocytoma, and has symptoms including seizures, headache and motor manifestations. An important gene associated with Grade Iii Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Temodar and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are Decreased viability in esophageal squamous lineage and Reduced mammosphere formation

Disease Ontology : 12 An astrocytoma that is characterized by cells with regular, round to oval nuclei.

Related Diseases for Grade Iii Astrocytoma

Diseases related to Grade Iii Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 240)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 31.3 GFAP IDH2 TP53
2 oligoastrocytoma 30.4 GFAP IDH2 MGMT
3 pleomorphic xanthoastrocytoma 30.2 GFAP MGMT TP53
4 glioblastoma multiforme 30.1 CDK4 CDKN2A DMBT1 EGFR GFAP MDM2
5 glioblastoma 30.1 CDK4 CDKN2A CDKN2B DMBT1 EGFR IDH2
6 fibrillary astrocytoma 30.0 GFAP IDH2 MGMT PCNA TP53
7 anaplastic oligodendroglioma 29.9 CDKN2A EGFR GFAP IDH2 MGMT
8 arteriovenous malformation 29.9 MMP9 PTEN VEGFA
9 renal cell carcinoma, nonpapillary 29.8 EGFR MMP2 MMP9 VEGFA
10 gliosarcoma 29.7 CDK4 EGFR GFAP MGMT MMP2 MMP9
11 medulloblastoma 29.7 CDK4 CDKN2B DMBT1 EGFR GFAP MGMT
12 glioma 29.3 CDK4 CDKN2A DMBT1 EGFR IDH2 MDM2
13 colorectal cancer 28.8 CDK4 CDKN2A EGFR MDM2 MGMT MMP2
14 oligodendroglioma 28.4 CDKN2A CDKN2B EGFR GFAP IDH2 MGMT
15 cellular ependymoma 10.3 GFAP TP53
16 cerebral convexity meningioma 10.3 GFAP TP53
17 bladder squamous cell carcinoma 10.3 CDKN2A TP53
18 bizarre leiomyoma 10.3 CDKN2A PCNA
19 actinic cheilitis 10.3 MDM2 TP53
20 malignant peritoneal mesothelioma 10.3 CDKN2A EGFR
21 undifferentiated embryonal sarcoma of the liver 10.3 CDK4 MDM2
22 preretinal fibrosis 10.3 GFAP VEGFA
23 frontal convexity meningioma 10.3 GFAP TP53
24 brain ependymoma 10.3 EGFR TP53
25 gliofibroma 10.3 GFAP TP53
26 zika virus infection 10.3 MDM2 TP53
27 protoplasmic astrocytoma 10.3 GFAP IDH2 TP53
28 oral leukoplakia 10.2 CDKN2A PCNA TP53
29 astrocytoma 10.2
30 suppressor of tumorigenicity 3 10.2 CDKN2A PCNA TP53
31 gemistocytic astrocytoma 10.2 GFAP IDH2 PTEN
32 intestinal disease 10.2 EGFR TP53 VEGFA
33 male reproductive system disease 10.2 PTEN TP53 VEGFA
34 ependymoma 10.2 EGFR GFAP MGMT
35 basaloid squamous cell carcinoma 10.2 CDKN2A EGFR TP53
36 ring chromosome 7 10.2 CDK4 MDM2 TP53
37 inverted papilloma 10.2 CDKN2A PCNA TP53
38 necrotizing sialometaplasia 10.2 CDKN2A GFAP TP53
39 acute lymphocytic leukemia 10.2 CDKN2A CDKN2B TP53
40 pre-malignant neoplasm 10.2 CDKN2A EGFR TP53
41 vulva cancer 10.2 CDKN2A EGFR TP53
42 gastric lymphoma 10.2 PCNA TP53 VEGFA
43 oropharynx cancer 10.2 CDKN2A EGFR TP53
44 juvenile pilocytic astrocytoma 10.2 CDKN2A GFAP TP53
45 verrucous carcinoma 10.2 CDKN2A MDM2 TP53
46 penile cancer 10.2 CDKN2A EGFR TP53
47 central nervous system lymphoma 10.2 CDKN2A MGMT TP53
48 in situ carcinoma 10.2 CDKN2A EGFR TP53
49 periosteal osteogenic sarcoma 10.2 CDK4 MDM2 TP53
50 anaplastic ependymoma 10.2 GFAP MDM2 PTEN

Graphical network of the top 20 diseases related to Grade Iii Astrocytoma:



Diseases related to Grade Iii Astrocytoma

Symptoms & Phenotypes for Grade Iii Astrocytoma

UMLS symptoms related to Grade Iii Astrocytoma:


seizures, headache, motor manifestations, sensory manifestations

GenomeRNAi Phenotypes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.7 APOD BSG CDKN2A DMBT1 GFAP IDH2
2 Reduced mammosphere formation GR00396-S 9.17 CDK4 EGFR IDH2 MDM2 MMP2 PCNA

MGI Mouse Phenotypes related to Grade Iii Astrocytoma:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10.49 APOD BSG CDK4 CDKN2A CDKN2B DMBT1
2 growth/size/body region MP:0005378 10.46 BSG CDK4 CDKN2A EGFR GFAP MDM2
3 homeostasis/metabolism MP:0005376 10.44 APOD CDK4 CDKN2A CDKN2B DMBT1 EGFR
4 cardiovascular system MP:0005385 10.43 APOD CDK4 CDKN2A EGFR GFAP IDH2
5 immune system MP:0005387 10.43 BSG CDK4 CDKN2A CDKN2B DMBT1 EGFR
6 cellular MP:0005384 10.42 CDK4 CDKN2A CDKN2B DMBT1 EGFR GFAP
7 behavior/neurological MP:0005386 10.4 APOD CDK4 CDKN2A GFAP MDM2 MMP9
8 hematopoietic system MP:0005397 10.39 BSG CDK4 CDKN2A CDKN2B EGFR MDM2
9 endocrine/exocrine gland MP:0005379 10.37 BSG CDK4 CDKN2A CDKN2B EGFR MDM2
10 digestive/alimentary MP:0005381 10.35 CDK4 CDKN2A DMBT1 EGFR GFAP MDM2
11 neoplasm MP:0002006 10.35 CDK4 CDKN2A CDKN2B DMBT1 EGFR IDH2
12 nervous system MP:0003631 10.3 APOD CDK4 CDKN2A EGFR GFAP MDM2
13 integument MP:0010771 10.29 CDK4 CDKN2A CDKN2B EGFR MDM2 MMP9
14 muscle MP:0005369 10.27 CDK4 CDKN2A EGFR GFAP MDM2 MMP2
15 embryo MP:0005380 10.25 CDK4 CDKN2A DMBT1 EGFR MDM2 PDGFRA
16 liver/biliary system MP:0005370 10.13 BSG CDK4 CDKN2A EGFR MDM2 PTEN
17 no phenotypic analysis MP:0003012 10.13 CDKN2A CDKN2B EGFR MDM2 MGMT OLIG2
18 limbs/digits/tail MP:0005371 10.08 EGFR MDM2 MMP9 PDGFRA PTEN TP53
19 normal MP:0002873 10.06 CDK4 EGFR GFAP MDM2 MMP2 PDGFRA
20 reproductive system MP:0005389 10.03 BSG CDK4 CDKN2A CDKN2B EGFR MDM2
21 renal/urinary system MP:0005367 10.02 CDK4 CDKN2B DMBT1 EGFR MDM2 MMP9
22 pigmentation MP:0001186 9.91 CDK4 CDKN2A EGFR MDM2 PDGFRA PTEN
23 respiratory system MP:0005388 9.9 BSG CDKN2A EGFR MGMT MMP2 MMP9
24 skeleton MP:0005390 9.65 CDKN2A EGFR MDM2 MMP2 MMP9 OLIG2
25 vision/eye MP:0005391 9.32 CDK4 CDKN2A EGFR GFAP MMP2 MMP9

Drugs & Therapeutics for Grade Iii Astrocytoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999

Drugs for Grade Iii Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 154-93-8 2578
2
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
3
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
4
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
5
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 85622-93-1 5394
6
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 4342-03-4 5351166
7
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 216974-75-3
8
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
9
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
10
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
11
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
12
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
15
Valproic Acid Approved, Investigational Phase 3,Phase 1,Phase 2 99-66-1 3121
16 tannic acid Approved Phase 3,Phase 2,Not Applicable
17
Benzocaine Approved, Investigational Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
18
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
19
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
20
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
21
Dopamine Approved Phase 3,Phase 2,Early Phase 1,Not Applicable 51-61-6, 62-31-7 681
22
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
23
Cyproheptadine Approved Phase 3 129-03-3 2913
24
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
25
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
26
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
27
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538 444795
28 Semustine Experimental, Investigational Phase 3 13909-09-6
29 Mitolactol Investigational Phase 3 10318-26-0
30 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
31 Dianhydrogalactitol Investigational Phase 3 23261-20-3
32 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
35 Ether Phase 3,Phase 2,Phase 1
36 Photosensitizing Agents Phase 3,Phase 2,Phase 1
37 Dihematoporphyrin Ether Phase 3,Phase 2,Phase 1
38 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable
39 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
40 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
41 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
42 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
43 Antimitotic Agents Phase 3,Phase 1,Phase 2
44 Anti-Infective Agents Phase 3,Phase 2,Phase 1
45 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
47 Antifungal Agents Phase 2, Phase 3,Phase 1
48 Keratolytic Agents Phase 3,Phase 1,Phase 2
49 Histone Deacetylase Inhibitors Phase 2, Phase 3,Phase 1
50 Antibodies Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 381)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
3 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
4 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
5 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
6 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
7 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
8 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
9 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
10 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
11 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
12 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
15 Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
16 Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Recruiting NCT03633552 Phase 3 Temozolomide
17 International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
18 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
19 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
20 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
21 The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Active, not recruiting NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
22 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3 temozolomide
23 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Active, not recruiting NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
24 Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases Not yet recruiting NCT03732482 Phase 2, Phase 3 Temozolomide capsules
25 Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma Terminated NCT00761280 Phase 3 trabedersen;temozolomide;carmustine;lomustine
26 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
27 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
28 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
29 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
30 Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Unknown status NCT02238496 Phase 2 Perifosine;Temsirolimus
31 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
32 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
33 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
34 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
35 Bevacizumab in Recurrent Grade II and III Glioma Unknown status NCT01164189 Phase 2 Temozolomide
36 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
37 Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma Completed NCT00003470 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
38 Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma Completed NCT00003537 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
39 Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma Completed NCT00301418 Phase 1, Phase 2 Erlotinib
40 A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Completed NCT00606008 Phase 2 Sunitinib Malate
41 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma Completed NCT00003621 Phase 2 carmustine;cisplatin;etoposide
42 Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse Completed NCT00003775 Phase 2 leflunomide
43 SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) Completed NCT00783393 Phase 2 Temozolomide
44 BNCT to Treat Glioma That Has Progressed Following Radiotherapy Completed NCT00115440 Phase 1, Phase 2
45 Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma Completed NCT00004017 Phase 2
46 Combination Chemotherapy for Patients With Brain Cancer Completed NCT00002814 Phase 2 paclitaxel;topotecan hydrochloride
47 Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma Completed NCT00409214 Phase 2 LS11 (talaporfin sodium)
48 A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas Completed NCT00921167 Phase 2 Bevacizumab/Irinotecan
49 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
50 Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02) Completed NCT00589875 Phase 2 Valacyclovir

Search NIH Clinical Center for Grade Iii Astrocytoma

Genetic Tests for Grade Iii Astrocytoma

Anatomical Context for Grade Iii Astrocytoma

MalaCards organs/tissues related to Grade Iii Astrocytoma:

41
Brain, Spinal Cord, T Cells, Bone, Endothelial, Myeloid, Breast

Publications for Grade Iii Astrocytoma

Articles related to Grade Iii Astrocytoma:

(show top 50) (show all 246)
# Title Authors Year
1
Erratum: Whole-exome sequencing identifies germline mutation in <i>TP53</i> and <i>ATRX</i> in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. ( 29858379 )
2018
2
Anaplastic Astrocytoma in a Child With Coffin-Siris Syndrome and a Germline SMARCE1 Mutation: A Case Report. ( 30499906 )
2018
3
Recurrence of spinal anaplastic astrocytoma in a cat after surgical treatment and long-term follow-up. ( 29065804 )
2018
4
Concomitant IDH wild-type glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome. ( 29130549 )
2018
5
cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. ( 29497819 )
2018
6
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. ( 29564591 )
2018
7
Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. ( 29602769 )
2018
8
Diffusely Infiltrating Cerebellar Anaplastic Astrocytoma Effectively Controlled with Bevacizumab: Case Report and Literature Review. ( 29704688 )
2018
9
Two successful pregnancies following fertility preservation in a patient with anaplastic astrocytoma: a case report. ( 29739361 )
2018
10
Anaplastic astrocytoma and pituitary macroadenoma within the same patient: A rare case of intracranial collision tumor. ( 29766961 )
2018
11
Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma. ( 29772361 )
2018
12
The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma. ( 30035459 )
2018
13
Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. ( 28870792 )
2017
14
Benefit with adjuvant chemotherapy in anaplastic astrocytoma. ( 28801187 )
2017
15
Crossed Aphasia in a Patient with Anaplastic Astrocytoma of the Non-Dominant Hemisphere. ( 29299104 )
2017
16
Anaplastic astrocytoma with aquaporin-4 positive in CSF: A case report. ( 29390462 )
2017
17
Retinal Metastases From Anaplastic Astrocytoma. ( 28864383 )
2017
18
The Mystery of Multiple Masses: A Case of Anaplastic Astrocytoma. ( 28775924 )
2017
19
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. ( 27994066 )
2017
20
A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma. ( 28288919 )
2017
21
Commentary on "Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813". ( 28340188 )
2017
22
Anaplastic astrocytoma cells not detectable on autopsy following long-term temozolomide treatment: A case report. ( 28451406 )
2017
23
Extracranial bone metastases from recurrent anaplastic astrocytoma on FDG PET/CT: A case report a care-compliant article. ( 28591062 )
2017
24
Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes. ( 28629398 )
2017
25
Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. ( 28675067 )
2017
26
Comparison of chemoradiotherapy with radiotherapy alone for "biopsy only" anaplastic astrocytoma. ( 28978179 )
2017
27
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27231756 )
2016
28
Distinctive Genetic Profile With IDH1, TP53, and MLH1 Mutations in a Radiation-Induced Anaplastic Astrocytoma. ( 26185030 )
2016
29
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27314913 )
2016
30
Ollier disease with anaplastic astrocytoma: A review of the literature and a unique case. ( 27656320 )
2016
31
Influence of insurance status and income in anaplastic astrocytoma: an analysis of 4325 patients. ( 27864706 )
2016
32
Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma : A dosimetric comparison. ( 27334276 )
2016
33
Network analysis of microRNAs, transcription factors, target genes and host genes in human anaplastic astrocytoma. ( 27347075 )
2016
34
Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy. ( 27401155 )
2016
35
Rapid increase in cystic volume of an anaplastic astrocytoma misdiagnosed as neurocysticercosis: A case report. ( 27698865 )
2016
36
Somatic BRAF c.1799T>A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities. ( 26360803 )
2016
37
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( 26729269 )
2016
38
Superior Efficacy of Gross Total Resection in Anaplastic Astrocytoma Patients Relative to Glioblastoma Patients. ( 26924115 )
2016
39
Anaplastic astrocytoma. ( 27230974 )
2016
40
Metachronous spinal metastases from supratentorial anaplastic astrocytoma. ( 25767596 )
2015
41
An infant with hyperalertness, hyperkinesis, and failure to thrive: a rare diencephalic syndrome due to hypothalamic anaplastic astrocytoma. ( 26337554 )
2015
42
Anaplastic astrocytoma mimicking herpes simplex encephalitis in 13-year old girl. ( 26272584 )
2015
43
Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. ( 25793136 )
2015
44
Intramedullary spinal glioblastoma metastasis from anaplastic astrocytoma of cerebellum: A case report and review of the literature. ( 26396627 )
2015
45
Chronic Phase Intracranial Hemorrhage Caused by Ruptured Pseudoaneurysm Induced by Carmustine Wafer Implantation for Insulo-opercular Anaplastic Astrocytoma: A Case Report. ( 26423018 )
2015
46
Nuclear Localization Signal-Enhanced Polyurethane-Short Branch Polyethylenimine-Mediated Delivery of Let-7a Inhibited Cancer Stem-Like Properties by Targeting the 3'-UTR of HMGA2 in Anaplastic Astrocytoma. ( 24898358 )
2015
47
A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. ( 25471051 )
2015
48
Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. ( 25563816 )
2015
49
Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure. ( 25577400 )
2015
50
Imaging findings of anaplastic astrocytoma in a child with maple syrup urine disease: a case report. ( 26084772 )
2015

Variations for Grade Iii Astrocytoma

ClinVar genetic disease variations for Grade Iii Astrocytoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ATRX NM_000489.4(ATRX): c.5579A> G (p.Asn1860Ser) single nucleotide variant Benign rs45439799 GRCh37 Chromosome X, 76856021: 76856021
2 ATRX NM_000489.4(ATRX): c.5579A> G (p.Asn1860Ser) single nucleotide variant Benign rs45439799 GRCh38 Chromosome X, 77600552: 77600552
3 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
4 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230

Expression for Grade Iii Astrocytoma

Search GEO for disease gene expression data for Grade Iii Astrocytoma.

Pathways for Grade Iii Astrocytoma

Pathways related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CDK4 CDKN2A CDKN2B EGFR GFAP MDM2
2
Show member pathways
13.76 CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
3
Show member pathways
13.16 CDK4 CDKN2A CDKN2B MDM2 TP53 VEGFA
4
Show member pathways
13.04 CDK4 EGFR MDM2 PDGFRA PTEN TP53
5
Show member pathways
13.02 CDK4 CDKN2A EGFR MDM2 MMP9 PCNA
6
Show member pathways
12.82 CDK4 CDKN2A CDKN2B EGFR PTEN TP53
7
Show member pathways
12.77 CDK4 CDKN2A EGFR MDM2 MMP9 PCNA
8
Show member pathways
12.75 EGFR MDM2 PDGFRA PTEN TP53
9
Show member pathways
12.73 CDK4 MDM2 MGMT PCNA TP53
10 12.72 CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
11
Show member pathways
12.62 CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
12
Show member pathways
12.58 EGFR MDM2 MMP2 MMP9 TP53
13 12.56 CDK4 CDKN2A MDM2 MGMT PCNA TP53
14 12.48 CDK4 CDKN2A CDKN2B PCNA PDGFRA TP53
15
Show member pathways
12.46 EGFR MDM2 PDGFRA TP53
16 12.45 CDKN2A EGFR MDM2 MMP9 PDGFRA PTEN
17
Show member pathways
12.44 CDK4 CDKN2A CDKN2B EGFR
18
Show member pathways
12.44 CDK4 CDKN2A MDM2 PTEN TP53
19
Show member pathways
12.41 MDM2 PCNA PTEN TP53
20 12.4 CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
21
Show member pathways
12.37 CDK4 CDKN2A CDKN2B TP53
22
Show member pathways
12.37 CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
23 12.35 CDK4 CDKN2A CDKN2B MDM2 TP53
24 12.34 EGFR MDM2 MMP2 MMP9 TP53 VEGFA
25
Show member pathways
12.28 CDK4 MDM2 PTEN TP53
26
Show member pathways
12.26 CDK4 EGFR MDM2 PDGFRA PTEN TP53
27 12.24 EGFR MMP2 MMP9 TP53 VEGFA
28 12.21 CDK4 CDKN2A CDKN2B MDM2 PTEN TP53
29 12.18 CDK4 EGFR MDM2 PDGFRA PTEN TP53
30 12.17 CDK4 EGFR MDM2 PTEN TP53 VEGFA
31
Show member pathways
12.16 EGFR MDM2 MMP2 PTEN
32 12.14 MMP2 MMP9 TP53 VEGFA
33
Show member pathways
12.13 CDKN2B EGFR MDM2 PTEN
34 12.12 CDKN2A MDM2 MMP2 TP53 VEGFA
35 12.09 EGFR MDM2 MMP2 PCNA PTEN TP53
36 12.06 CDK4 EGFR GFAP MMP9 TP53
37 12.04 CDKN2A MDM2 PTEN TP53
38 12.04 MMP2 MMP9 TP53 VEGFA
39 12 CDKN2A MDM2 PCNA PTEN TP53
40 11.94 CDK4 CDKN2B PTEN TP53
41 11.9 CDK4 MDM2 PCNA TP53
42 11.87 EGFR MDM2 PTEN
43 11.86 MMP2 MMP9 PDGFRA
44 11.83 GFAP OLIG1 OLIG2 PDGFRA VEGFA
45 11.82 CDK4 MMP9 TP53
46 11.8 CDK4 CDKN2A EGFR MDM2 MGMT PDGFRA
47 11.77 CDKN2A MDM2 TP53
48
Show member pathways
11.76 CDKN2A MDM2 TP53
49 11.76 EGFR PDGFRA PTEN TP53
50 11.76 CDKN2A MDM2 MMP2 TP53 VEGFA

GO Terms for Grade Iii Astrocytoma

Biological processes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.99 DMBT1 MDM2 PCNA PDGFRA TP53
2 positive regulation of gene expression GO:0010628 9.97 CDKN2A MDM2 PTEN TP53 VEGFA
3 angiogenesis GO:0001525 9.92 APOD MMP2 PTEN VEGFA
4 positive regulation of cell migration GO:0030335 9.92 EGFR MMP9 PDGFRA VEGFA
5 positive regulation of cell proliferation GO:0008284 9.91 CDK4 EGFR MDM2 PDGFRA PTEN VEGFA
6 positive regulation of apoptotic process GO:0043065 9.89 CDK4 CDKN2A MMP9 PTEN TP53
7 extracellular matrix organization GO:0030198 9.88 BSG GFAP MMP9 PDGFRA
8 response to drug GO:0042493 9.85 APOD CDK4 MDM2 MGMT PTEN
9 epithelial cell differentiation GO:0030855 9.79 DMBT1 PCNA VEGFA
10 extracellular matrix disassembly GO:0022617 9.73 BSG MMP2 MMP9
11 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.72 MDM2 PCNA TP53
12 cellular response to amino acid stimulus GO:0071230 9.71 EGFR MMP2 PDGFRA
13 positive regulation of fibroblast proliferation GO:0048146 9.7 CDK4 EGFR PDGFRA
14 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.69 MDM2 MMP2 MMP9
15 embryo implantation GO:0007566 9.65 BSG MMP2 MMP9
16 replicative senescence GO:0090399 9.63 CDKN2A TP53
17 amyloid fibril formation GO:1990000 9.61 CDKN2A MDM2
18 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.6 EGFR TP53
19 cellular response to reactive oxygen species GO:0034614 9.58 EGFR MMP9 PDGFRA
20 cellular response to hypoxia GO:0071456 9.56 MDM2 PTEN TP53 VEGFA
21 negative regulation of apoptotic process GO:0043066 9.56 EGFR MDM2 MGMT MMP9 PDGFRA PTEN
22 cellular response to actinomycin D GO:0072717 9.37 MDM2 TP53
23 positive regulation of DNA repair GO:0045739 9.33 EGFR MGMT PCNA
24 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.32 PDGFRA VEGFA
25 obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 8.92 CDK4 CDKN2A CDKN2B PTEN
26 multicellular organism development GO:0007275 10.11 DMBT1 EGFR OLIG1 OLIG2 PDGFRA TP53

Molecular functions related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.77 CDKN2A CDKN2B EGFR PTEN TP53
2 enzyme binding GO:0019899 9.65 EGFR MDM2 PCNA PTEN TP53
3 identical protein binding GO:0042802 9.56 EGFR GFAP MDM2 MMP9 PCNA PTEN
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.4 CDKN2A CDKN2B
5 disordered domain specific binding GO:0097718 9.33 CDKN2A MDM2 TP53
6 platelet-derived growth factor receptor binding GO:0005161 8.8 PDGFRA PTEN VEGFA
7 protein binding GO:0005515 10.25 APOD BSG CDK4 CDKN2A CDKN2B DMBT1

Sources for Grade Iii Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....